CervoMed upgraded to Buy from Hold at D. Boral Capital

D. Boral Capital upgraded CervoMed (CRVO) to Buy from Hold with a $10 price target The firm’s analysis suggests a combination of factors contributed to RewinD-LB trial outcome, primarily a dose-effect issue likely driven by lower than expected bioavailability, potentially due to an older drug batch. The analyst believes the company is taking the right corrective steps to address this, including exploring a higher dose. Upcoming data from the open-label extension trial, expected soon, should provide further clarity and help validate this thesis, the analyst tells investors in a research note.